Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Regulatory Affairs Japanese Pharmaceutical Companies Eli Lilly Phase 3 Trials FDA Approvals Neurocrine Biosciences AstraZeneca Funding Sources Innovation in Healthcare Radiopharmaceuticals Boehringer Ingelheim Wave Life Sciences Pharmaceutical Industry Trends Market Impact Ivonescimab Cancer Treatments Phase 2 Trials Biologics License Application Monoclonal Antibodies

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

The failed sweat‑chloride readout prompted the program halt, triggering a near‑92% premarket share collapse as the company reviews next steps.

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

One Infusion Cuts LDL by Up to 62% in Early Gene‑Editing Trial

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Study Finds Most With New Focal Epilepsy Need a Year to Gain Seizure Control